We serve Chemical Name:3-Amino-1H-pyrazole-4-carboxamide CAS:5334-31-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-Amino-1H-pyrazole-4-carboxamide
CAS.NO:5334-31-6
Synonyms:3-Amino-4-pyrazolecarboxamide;1H-Pyrazole-4-carboxamide, 3-amino-;5-amino-1H-pyrazole-4-carboxamide;1H-pyrazole-4-carboxamide, 5-amino-;3-Amino-1H-pyrazole-4-carboxamide;EINECS 226-252-3
Molecular Formula:C4H6N4O
Molecular Weight:126.117
HS Code:2933199090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:454.3±25.0 °C at 760 mmHg
Density:1.5±0.1 g/cm3
Index of Refraction:1.708
PSA:97.79000
Exact Mass:126.054161
LogP:-0.36
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 3-Amino-4-pyrazolecarboxamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,EINECS 226-252-3 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,EINECS 226-252-3 Use and application,EINECS 226-252-3 technical grade,usp/ep/jp grade.
Related News: Fate Therapeutics�� iPSC product platform is supported by an intellectual property portfolio of over 250 issued patents and 150 pending patent applications. 3-Amino-1H-pyrazole-4-carboxamide manufacturer Fate Therapeutics�� iPSC product platform is supported by an intellectual property portfolio of over 250 issued patents and 150 pending patent applications. 3-Amino-1H-pyrazole-4-carboxamide supplier ICIG is a privately owned industrial holding company focusing on mid-sized chemicals and pharmaceutical businesses. 3-Amino-1H-pyrazole-4-carboxamide vendor The two trials studied similar patient populations, Tendler said, but VMP was an old standard of care that’s not really used today in the U.S. Still, Tendler believes the two regimens may both have roles to play based on each patient’s ability to tolerate them. Whichever cocktail physicians choose, the two phase 3 studies have confirmed the benefit of Darzalex in transplant-ineligible patients, he added. 3-Amino-1H-pyrazole-4-carboxamide factory This also includes its anti-tau pipeline, with the FDA’s approval having “implications for AD programmes targeting Tau,” according to Jefferies.
